# Theravance Biopharma, Inc. (TBPH) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Theravance Biopharma, Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/TBPH/mda/fy2025/): filed 2026-03-23; accession 0001104659-26-033077 (https://www.sec.gov/Archives/edgar/data/1583107/000110465926033077/tbph-20251231x10k.htm); latest 10-K
- [FY 2024 MD&A](/company/TBPH/mda/fy2024/): filed 2025-03-07; accession 0001558370-25-002447 (https://www.sec.gov/Archives/edgar/data/1583107/000155837025002447/tbph-20241231x10k.htm)
- [FY 2023 MD&A](/company/TBPH/mda/fy2023/): filed 2024-03-01; accession 0001558370-24-002267 (https://www.sec.gov/Archives/edgar/data/1583107/000155837024002267/tbph-20231231x10k.htm)
- [FY 2022 MD&A](/company/TBPH/mda/fy2022/): filed 2023-03-01; accession 0001558370-23-002595 (https://www.sec.gov/Archives/edgar/data/1583107/000155837023002595/tbph-20221231x10k.htm)
- [FY 2021 MD&A](/company/TBPH/mda/fy2021/): filed 2022-02-28; accession 0001558370-22-002373 (https://www.sec.gov/Archives/edgar/data/1583107/000155837022002373/tbph-20211231x10k.htm)

Back to /company/TBPH/